Last reviewed · How we verify
Fycompa
Fycompa is a Small molecule drug developed by Eisai Inc.. It is currently FDA-approved for Idiopathic generalized epilepsy, Partial seizure, Secondarily generalized seizures. Also known as: Perampanel, E2007, AMPA - type Glutamate Receptor Antagonist.
At a glance
| Generic name | Fycompa |
|---|---|
| Also known as | Perampanel, E2007, AMPA - type Glutamate Receptor Antagonist |
| Sponsor | Eisai Inc. |
| Target | Glutamate receptor ionotropic AMPA |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Idiopathic generalized epilepsy
- Partial seizure
- Secondarily generalized seizures
Common side effects
- Dizziness
- Somnolence
- Fatigue
- Irritability
- Falls
- Nausea
- Ataxia
- Balance disorder
- Gait disturbance
- Vertigo
- Weight gain
- Headache
Key clinical trials
- Senicapoc and Perampanel for Newly Diagnosed Glioblastoma (EARLY_PHASE1)
- Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus (PHASE4)
- A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy (PHASE2)
- An Extended Access Program (EAP) for Perampanel
- Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations (PHASE1)
- PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest (PHASE2)
- A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
- A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fycompa CI brief — competitive landscape report
- Fycompa updates RSS · CI watch RSS
- Eisai Inc. portfolio CI
Frequently asked questions about Fycompa
What is Fycompa?
Fycompa is a Small molecule drug developed by Eisai Inc., indicated for Idiopathic generalized epilepsy, Partial seizure, Secondarily generalized seizures.
What is Fycompa used for?
Fycompa is indicated for Idiopathic generalized epilepsy, Partial seizure, Secondarily generalized seizures.
Who makes Fycompa?
Fycompa is developed and marketed by Eisai Inc. (see full Eisai Inc. pipeline at /company/eisai).
Is Fycompa also known as anything else?
Fycompa is also known as Perampanel, E2007, AMPA - type Glutamate Receptor Antagonist.
What development phase is Fycompa in?
Fycompa is FDA-approved (marketed).
What are the side effects of Fycompa?
Common side effects of Fycompa include Dizziness, Somnolence, Fatigue, Irritability, Falls, Nausea.
What does Fycompa target?
Fycompa targets Glutamate receptor ionotropic AMPA.
Related
- Target: All drugs targeting Glutamate receptor ionotropic AMPA
- Manufacturer: Eisai Inc. — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Idiopathic generalized epilepsy
- Indication: Drugs for Partial seizure
- Indication: Drugs for Secondarily generalized seizures
- Also known as: Perampanel, E2007, AMPA - type Glutamate Receptor Antagonist
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing